CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Greece

  • ID: 4438994
  • Report
  • Region: Greece
  • 149 pages
  • GlobalData
1 of 3
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Greece

Summary

Pharmaceutical industry is one of the major contributors to the Greek economy, adding about 4% to net GDP. However, the debt crisis, subsequent austerity measures and clawbacks have led to a crisis in the industry. The economic crisis and the subsequent policy changes have affected the growth of the pharmaceutical industry. The value of the market decreased from over $10Billion in 2009 to below $7Billion in 2016, at a negative Compound Annual Growth Rate (CAGR) of around 6.3%. Sales to pharmacies/wholesalers declined by about 2.5% in 2015. However, sales to hospitals increased by over 5.5% as compared to 2014.

Pharmaceutical market of Greece, based on sales of medicinal products in pharmacies, wholesalers and hospitals, amounted to over $7 Billion in 2015. Pharmacies and wholesalers sales saw a decline of 2.7% in 2015. However, sales to hospitals increased by around 5.7%. Prescription drugs that have a wholesaler price of less than €20 ($26.1) make up for more than 63% of the market.

Medical device market was worth around $1.3 Billion in 2009 and had crossed $1.5 Billion in 2016. It is forecast to grow at a CAGR of around 3.5% from over $1.6 Billion in 2017 to around $1.85Billion in 2021. The main segments are in this market are In Vitro Diagnostics (IVD), diabetes care devices, cardiovascular devices, ophthalmic devices and orthopedic devices.

The report "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Greece", provides an overview of the healthcare market of Greece and the key factors driving it.

In particular, this report provides the following:
  • Provides an overview of the pharmaceutical and medical device market of Greece, including the market size; market segmentation by generic, Over-The-Counter (OTC), biologic and biosimilar products; and the key drivers and barriers for the market.
  • Covers the country’s reimbursement and payer landscape, as well as the regulatory landscape. The reimbursement and payer landscape section elaborates on the features of the healthcare reimbursement process for Greece.
  • Provides a detailed analysis of the healthcare policies of Greece. It analyzes its healthcare infrastructure and healthcare expenditure.
  • Provides an overview of the opportunities and challenges for growth that exist in the healthcare market of Greece.
Companies mentioned in this report: Pfizer, Novartis, Sanofi, Astra Zeneca and GlaxoSmithKline

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Greece, and includes:
  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Pfizer, Novartis, Sanofi, Astra Zeneca and GlaxoSmithKline (GSK). Profiles and SWOT analyses of the major players in the medical device market: Sanofi, Roche, Essilor and Alcon.
  • An insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
  • Detailed analysis of the country’s healthcare environment, demographics, healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Greek healthcare market
Reasons to buy

This report will enhance your decision-making capability by allowing you to:
  • Develop business strategies by understanding the trends shaping and driving Greece’s healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Greece’s healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents

2 Executive Summary

3 Introduction
3.1 Report Guidance

4 Overview of Pharmaceutical and Medical Device Markets
4.1 Pharmaceutical Market
4.1.1 Market Overview
4.1.2 Pharmaceutical Exports and Imports
4.1.3 Supply Channels
4.1.4 Market Segments
4.1.5 Major Therapeutic Areas
4.1.6 Major Players
4.2 Medical Device Market
4.2.1 Market Overview
4.2.2 Overview of Top Five Segments
4.2.3 Diagnostic Market
4.2.4 Major Players
4.3 Market Drivers and Barriers
4.3.1 Drivers
4.3.2 Barriers

5 Market Access
5.1 Overview of Healthcare System
5.2 Reimbursement Process
5.2.1 Overview of Insurance Providers
5.2.2 Patient Share in Healthcare Expenditure
5.2.3 Price Trends of Pharmaceutical Products
5.2.4 Pricing Policies
5.3 Regulatory Landscape
5.3.1 Overview of Regulatory Agencies
5.3.2 Structure and Organization of the EOF
5.3.3 Market Authorization Procedure for Pharmaceutical Products
5.3.4 New Medical Device Approval Process
5.3.5 Licensing Process for Pharmaceutical and Medical Device Manufacturing
5.3.6 Intellectual Property Rights
5.3.7 Clinical Trial Regulations
5.3.8 Pharmaceutical Advertising Regulations
5.3.9 Pharmacy Regulations
5.3.10 Labeling and Packaging Regulations

6 Country Healthcare Landscape
6.1 Healthcare Policy Initiatives
6.2 Healthcare Infrastructure
6.2.1 Healthcare Facilities
6.2.2 Healthcare Parameters
6.2.3 Healthcare Personnel
6.2.4 Environmental Health
6.3 Healthcare Expenditure
6.3.1 Overview
6.3.2 Share of Public and Private Sectors
6.3.3 Major Components of Healthcare Expenditure
6.3.4 Spending in Pharmaceutical R&D
6.4 Trade Associations
6.4.1 Pharmacists’ Co-operative Federation
6.4.2 Hellenic Association of Pharmaceutical Companies
6.4.3 Panhellenic Association of Pharmaceutical Wholesalers
6.4.4 Hellenic Biotech Association
6.5 Conferences and Trade Fairs

7 Opportunities and Challenges
7.1 Opportunities
7.2 Challenges

8 Appendix
8.1 Abbreviations
8.2 Bibliography
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasts
8.3.4 Expert Panel
8.4 Contact
8.5 Disclaimer

List of Tables
Table 1: Pharmaceutical Market, Greece, Revenue ($bn), 2009-2016
Table 2: Pharmaceutical Market, Greece, Revenue ($bn), 2017-2021
Table 3: Pharmaceutical Market, Greece, Sales Distribution Based on Wholesale Price, 2016
Table 4: Pharmaceutical Market, Greece, Exports and Imports ($bn), 2009-2015
Table 5: Pharmaceutical Market, Greece, Generic Drugs Market Share (%), 2013-2016
Table 6: Pharmaceutical Market, Greece, EU Countries Generic Drugs Market Share by Volume (%), 2016
Table 7: Pharmaceutical Market, EU, Approved Biosimilars, 2016-2017
Table 8: Pharmaceutical Market, Greece, Generic Market ($m), 2010-2015
Table 9: Pharmaceutical Market, Greece, Major Therapeutic Areas, Revenue Share (%), 2015
Table 10: Pharmaceutical Market, Pfizer, Global, Late-Stage Pipeline, 2017
Table 11: Novartis, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2016
Table 12: Pharmaceutical Market, Novartis, Planned Filings, 2017-2020
Table 13: Pharmaceutical Market, Sanofi, Global, Late-Stage Pipeline, 2017
Table 14: Pharmaceutical Market, AstraZeneca, Greece, Major Products, 2016
Table 15: Pharmaceutical Market, AstraZeneca, Global, Late-Stage Pipeline, 2017
Table 16: Medical Device Market, Greece, Revenue ($bn), 2009-2016
Table 17: Medical Device Market, Greece, Revenue ($bn), 2017-2021
Table 18: Medical Device Market, Greece, Revenue ($m) and Market Share (%) by Segment, 2016
Table 19: In Vitro Diagnostics Market, Greece, Revenue ($m), 2009-2016
Table 20: Diabetes Care Devices Market, Greece, Revenue ($m), 2009-2016
Table 21: Orthopedic Devices, Greece, Revenue ($m) and Market Share (%) of Major Players, 2015
Table 22: Cardiovascular Device Market, Greece, Revenue ($m), 2009-2016
Table 23: Ophthalmic Device Market, Greece, Revenue ($m), 2009-2016
Table 24: Ophthalmic Device Market, Greece, Revenue ($m) and Market Share (%) of Major Players, 2015
Table 25: Cardiovascular Device Market, Greece, Revenue ($m), 2009-2016
Table 26: Cardiovascular Device Market, Greece, Revenue ($m), 2009-2016
Table 27: Diagnostic Market, Greece, Revenue ($m), 2017-2021
Table 28: Medical Device Market, Roche, Greece, Medical Device Pipeline, 2017
Table 29: Medical Device Market, Alcon, Global Products, 2017
Table 30: Healthcare Expenditure, Greece, Out-of-Pocket Expenditure (%), 2009-2016
Table 31: Market Access, Greece, Change in Price Index of Pharmaceutical Products (%), 2009-2016
Table 32: Market Access, Greece, Patent Fees, 2016
Table 33: Healthcare Infrastructure, Greece, Hospitals, 2009-2015
Table 34: Healthcare Infrastructure, Greece, Hospitals by Type, 2009-2015
Table 35: Healthcare Infrastructure, Greece, Diagnostic Units, 2007-2013
Table 36: Healthcare Infrastructure, Greece, Hospitals Beds (per 1,000 population), 2009-2016
Table 37: Demographics, Greece, Life Expectancy at Birth (years), 2009-2016
Table 38: Demographics, Greece, Life Expectancy at Birth (years), 2017-2021
Table 39: Demographics, Greece, Immunization Rate (%), 2009-2016
Table 40: Demographics, Greece, Major Causes of Mortality (number of deaths), 2014
Table 41: Demographics, Greece, Major Causes of Male Mortality (number of deaths), 2014
Table 42: Demographics, Greece, Major Causes of Female Mortality (number of deaths), 2014
Table 43: Demographics, Greece, Disability-Adjusted Life Years by Major Disease (‘000), 2015
Table 44: Healthcare Infrastructure, Greece, Doctors (per 1,000 population), 2009-2016
Table 45: Healthcare Infrastructure, Greece, Nurses (per 1,000 population), 2009-2016
Table 46: Healthcare Infrastructure, Greece, Dentists (per 1,000 population), 2009-2016
Table 47: Healthcare Infrastructure, Greece, Pharmacists (per 1,000 population), 2009-2016
Table 48: Healthcare Infrastructure, Greece, PM2.5 (µg per m³), 2009-2016
Table 49: Healthcare Infrastructure, Greece, CO2 Emissions (million tons), 2009-2016
Table 50: Healthcare Expenditure, Greece, Healthcare Expenditure as Percentage of GDP (%), 2009-2016
Table 51: Healthcare Expenditure, Greece, Public-Private Share of Expenditure (%), 2009-2016
Table 52: Healthcare Expenditure, Greece, Clawbacks & Rebates ($m), 2012-2016
Table 53: Healthcare Expenditure, Greece, Major Components of Healthcare Expenditure (%), 2015
Table 54: Healthcare Expenditure, Greece, Major Components of Healthcare Expenditure (%), 2015
Table 55: Healthcare Expenditure, Greece, Conferences and Trade Fairs, 2018

List of Figures
Figure 1: Pharmaceutical Market, Greece, Revenue ($bn), 2009-2021
Figure 2: Medical Device Market, Greece, Revenue ($bn), 2009-2021
Figure 3: Country Profile, Greece, 2017
Figure 4: Pharmaceutical Market, Greece, Revenue ($bn), 2009-2016
Figure 5: Pharmaceutical Market, Greece, Revenue ($bn), 2017-2021
Figure 6: Pharmaceutical Market, Greece, Sales Distribution Based on Wholesale Price, 2016
Figure 7: Pharmaceutical Market, Greece, Exports and Imports ($bn), 2009-2015
Figure 8: Pharmaceutical Market, Greece, Distribution Channels, 2016
Figure 9: Pharmaceutical Market, Greece, Generic Drugs Market Share (%), 2013-2016
Figure 10: Pharmaceutical Market, Greece, EU Countries Generic Drugs Market Share by Volume (%), 2016
Figure 11: Pharmaceutical Market, Greece, OTC Market ($m), 2010-2015
Figure 12: Pharmaceutical Market, Greece, Major Therapeutic Areas, Revenue Share (%), 2015
Figure 13: Medical Device Market, Greece, Revenue ($bn), 2009-2016
Figure 14: Medical Device Market, Greece, Revenue ($bn), 2017-2021
Figure 15: Medical Device Market, Greece, Revenue by Segment ($m), 2016
Figure 16: In Vitro Diagnostics Market, Greece, Revenue ($m), 2009-2016
Figure 17: Diabetes Care Devices Market, Greece, Revenue ($m), 2009-2016
Figure 18: Orthopedic Device Market, Greece, Market Share of Major Players (%), 2015
Figure 19: Cardiovascular Device Market, Greece, Revenue ($m), 2009-2016
Figure 20: Ophthalmic Device Market, Greece, Revenue ($m), 2009-2016
Figure 21: Ophthalmic Device Market, Greece, Market Share of Major Players (%), 2015
Figure 22: Cardiovascular Device Market, Greece, Revenue ($m), 2009-2016
Figure 23: Diagnostic Market, Greece, Revenue ($m), 2009-2016
Figure 24: Diagnostic Market, Greece, Revenue ($m), 2017-2021
Figure 25: Healthcare Market, Greece, Drivers and Barriers, 2017
Figure 26: Healthcare Market, Greece, Overview of Healthcare System, 2017
Figure 27: Healthcare Expenditure, Greece, Out-of-Pocket Expenditure (%), 2009-2016
Figure 28: Market Access, Greece, Change in Price Index of Pharmaceutical Products (%), 2009-2016
Figure 29: Market Access, Greece, Pricing Procedure, 2015
Figure 30: Market Access, EU, Centralized Procedure, Market Authorization, Pre-submission Phase, 2017
Figure 31: Market Access, EU, Centralized Procedure, Market Authorization, Pre-opinion Phase, 2017
Figure 32: Market Access, EU, Centralized Procedure, Market Authorization, Post-Opinion Phase, 2017
Figure 33: Market Access, EU, Decentralized Procedure, Market Authorization, 2017
Figure 34: Market Access, EU, Conformity Assessment of Class I Medical Devices, 2017
Figure 35: Market Access, EU, Conformity Assessment of Class IIa Medical Devices, 2017
Figure 36: Market Access, EU, Conformity Assessment of Class IIb Medical Devices, 2017
Figure 37: Market Access, EU, Conformity Assessment of Class III Medical Devices, 2017
Figure 38: Market Access, Greece, Patent Approval Process, 2016
Figure 39: Market Access, Greece, Patent Approval Process, 2016
Figure 40: Healthcare Infrastructure, Greece, Hospitals, 2009-2015
Figure 41: Healthcare Infrastructure, Greece, Hospitals by type, 2009-2015
Figure 42: Healthcare Infrastructure, Greece, Diagnostic Units, 2007-2013
Figure 43: Healthcare Infrastructure, Greece, Hospitals Beds (per 1,000 population), 2009-2016
Figure 44: Demographics, Greece, Life Expectancy at Birth (years), 2009-2016
Figure 45: Demographics, Greece, Life Expectancy at Birth (years), 2017-2021
Figure 46: Demographics, Greece, Immunization Rate (%), 2009-2016
Figure 47: Demographics, Greece, Major Causes of Mortality (number of deaths), 2014
Figure 48: Demographics, Greece, Major Causes of Male Mortality (number of deaths), 2014
Figure 49: Demographics, Greece, Major Causes of Female Mortality (number of deaths), 2014
Figure 50: Demographics, Greece, Major Diseases, Disability-Adjusted Life Years by Major Disease (‘000s), 2015
Figure 51: Healthcare Infrastructure, Greece, Doctors (per 1,000 population), 2009-2016
Figure 52: Healthcare Infrastructure, Greece, Nurses (per 1,000 population), 2009-2016
Figure 53: Healthcare Infrastructure, Greece, Dentists (per 1,000 population), 2009-2016
Figure 54: Healthcare Infrastructure, Greece, Pharmacists (per 1,000 population), 2009-2016
Figure 55: Healthcare Infrastructure, Greece, PM2.5 (µg per m³), 2009-2016
Figure 56: Healthcare Infrastructure, Greece, CO2 Emissions (million tons), 2009-2016
Figure 57: Healthcare Expenditure, Greece, Healthcare Expenditure as Percentage of GDP (%), 2009-2016
Figure 58: Healthcare Expenditure, Greece, Public-Private Share of Expenditure (%), 2009-2016
Figure 59: Healthcare Expenditure, Greece, Clawbacks & Rebates ($m), 2012-2016
Figure 60: Healthcare Expenditure, Greece, Major Components of Healthcare Expenditure (%), 2015
Figure 61: Healthcare Expenditure, Greece, Major Components of Clinical Trial Expenditure (%), 2015
Figure 62: Healthcare Market, Greece, Opportunities and Challenges, 2017
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll